1. Targeted Delivery: ACM Biolabs' delivery is designed to target antigen-presenting cells, requiring low amounts of payloads in ACMs, which is optimal for educating the immune system against virus antigens. 2. Effective Components: The ACM delivery is composed of a few components, enabling easy manufacturing and encapsulation of proteins, peptides, and mRNA. 3. Payload Protection: The company's payload is safeguarded at refrigerator temperatures, allowing for convenient storage and transport, especially for mRNA at 4°C. In 2013, ACM Biolabs was founded, focusing on the Biotechnology and Health Care industries, with its headquarters in Singapore. The company recently secured a $6.80M venture round investment on 19 September 2022, with Ritz Venture Capital as the investor.
ACM Biolabs
Singapore
19 employees
Venture round
Total: $6.80M
Biotechnology, Health Care
General Information
Singapore
BounceWatch is an independent company data service, not affiliated with ACM Biolabs. To contact ACM Biolabs, visit acmbiolabs.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does ACM Biolabs compare?
A PDF of ACM Biolabs and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting ACM Biolabs soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
Singapore Market
Biotechnology
About ACM Biolabs
Business keywords: nanotechnology, vaccines, therapeutics, targeted delivery, prophylactic treatment, therapeutic vaccines, infectious diseases, cancer treatment, dendritic cells, mRNA technology, artificial cell membrane, drug delivery platform, immunotherapy, antigen-presenting cells
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Venture Round | $6.80M | 1 |
|
19 Sep 2022 |
| Grant | Undisclosed | - |
|
27 May 2021 |
| Seed Round | Undisclosed | - |
|
01 Apr 2021 |
ACM Biolabs Alternatives & Competitors
View All Alternatives
Harnessing nature to program targeted, potent and tunable medicines
A genetic medicines company developing first-in-class, targeted nucleic acid therapeutics
Enabling a new generation of genomic medicines for patients with high unmet medical needs.
Abintus Bio, Inc.
FAQ About ACM Biolabs
Source: BounceWatch company record for ACM Biolabs, https://bouncewatch.com/company/acm-biolabs, updated 30 December 2024. When citing, please name BounceWatch and link this page.
